Innate Pharma S.A. ADS

GT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runwa...

Over 30 pharmaceutical companies are actively developing more than 30 pipeline drugs for cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin lymphoma affecting the skin. Key players including Prescient Therapeutics, Innate Pharma, and others are advancing promising therapies with various mechanisms of action through clinical trials. The market i...

The peripheral T-cell lymphoma (PTCL) treatment market is projected to grow at a 7% CAGR through 2036, driven by increasing disease incidence and expanding patient populations. The market was valued at USD 800 million in 2025, with the US accounting for 68% of the market. Multiple emerging therapies from major pharmaceutical companies are expecte...

Coherus Oncology announced the appointment of Arvind Sood as Chief Strategy and Corporate Affairs Officer, focusing on advancing innovative cancer therapeutics and driving revenues for LOQTORZI®.

The non-Hodgkin's lymphoma market is expected to grow significantly between 2025-2034, driven by increasing incidence, advancements in targeted therapies, emerging treatments, and improved early detection efforts.